Novo CEO talks about rebrand, corporate changes amid fight for obesity market share

• Novo Nordisk is rebranding to 'Novo' and updating its purpose statement to 'driving change for lasting health' to be more inclusive.
• The strategic evolution focuses on increasing speed, clarity, and customer obsession, adapting to a rapidly changing healthcare and consumer-like obesity market.
• The CEO expresses confidence in Wegovy's efficacy (17% weight loss) and the company's pipeline, viewing Medicare coverage for obesity drugs as an encouraging step.
• Novo Nordisk aims to educate employers to see GLP-1 treatments as an investment rather than a cost, due to their broader health benefits.
• The company emphasizes its long history of innovation and ability to reinvent itself to meet the demands of millions of patients.

Novo Nordisk's CEO, Mike Doustdar, discusses the company's rebrand to 'Novo' and a corporate culture shift aimed at evolving its strategy for lasting health. The changes are driven by the dynamic healthcare landscape, particularly the growing obesity market, where the company seeks to enhance speed, clarity, and customer obsession to regain market share and capitalize on significant growth opportunities.